Literature DB >> 6639835

Active metabolites of acenocoumarol: do they contribute to the therapeutic effect?

H H Thijssen, L G Baars.   

Abstract

The pharmacokinetics and pharmacodynamics of racemic acenocoumarol (AC), the amino (AM) and acetamido (AA) derivative were investigated in healthy volunteers after administration of a single oral (10 mg) dose. All three coumarins were rapidly absorbed from the gastrointestinal tract. The elimination half-lives were 10.9, 10.4, and 4.1 h, for AC, AM and AA, respectively. After the oral administration of AC, no AM and AA was detected in the plasma, and less than 1% of the dose was recovered in the urine (0-24 h) as AM. Renal clearance was the main route of elimination of AM and AA; the former by glomerular filtration, the latter by active excretion. Binding to serum proteins was the highest for AC (1.52% free). AM and AA were less tightly bound (about 3% free). AM or AA did not interfere with the AC plasma protein binding. The oral administration of AC resulted in a rise in prothrombin time with a maximum effect at 24 to 30 h. No anticoagulant activity was observed upon the administration of AM and AA. The results indicate that the compounds AM and AA, if they are formed out of AC at all, do not contribute to the anticoagulant activity of AC.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6639835      PMCID: PMC1428069          DOI: 10.1111/j.1365-2125.1983.tb02205.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Mechanism of p-nitrobenzoate reduction in liver: the possible role oc cytochrome P-450 in liver microsomes.

Authors:  J R Gillette; J J Kamm; H A Sasame
Journal:  Mol Pharmacol       Date:  1968-11       Impact factor: 4.436

2.  Comparison of the metabolism of nitrobenzene by hepatic microsomes and cecal microflora from Fischer-344 rats in vitro and the relative importance of each in vivo.

Authors:  A A Levin; J G Dent
Journal:  Drug Metab Dispos       Date:  1982 Sep-Oct       Impact factor: 3.922

3.  The relationship between nitro group reduction and the intestinal microflora.

Authors:  L A Wheeler; F B Soderberg; P Goldman
Journal:  J Pharmacol Exp Ther       Date:  1975-07       Impact factor: 4.030

4.  Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam.

Authors:  R Jochemsen; B R Van Beusekom; P Spoelstra; A R Janssens; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

5.  The importance of the intestinal microflora in nitrazepam metabolism in the rat [proceedings].

Authors:  D S Hewick; V Shaw
Journal:  Br J Pharmacol       Date:  1978-03       Impact factor: 8.739

6.  Anticoagulant activity of the enantiomers of acenocoumarol.

Authors:  T Meinertz; W Kasper; C Kahl; E Jähnchen
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

7.  Biotransformation and pharmacokinetics of acenocoumarol (Sintrom) in man.

Authors:  W Dieterle; J W Faigle; C Montigel; M Sulc; W Theobald
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

8.  Analysis of acenocoumarin and its amino and acetamido metabolites in body fluids by high-performance liquid chromatography.

Authors:  H H Thijssen; L G Baars; M J Reijnders
Journal:  J Chromatogr       Date:  1983-05-13

9.  May mothers taking acenocoumarol breast feed their infants?

Authors:  M Houwert-de Jong; L J Gerards; C A Tetteroo-Tempelman; F A de Wolff
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Pharmacokinetics of the enantiomers of acenocoumarol in man.

Authors:  J Godbillon; J Richard; A Gerardin; T Meinertz; W Kasper; E Jähnchen
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

  10 in total
  8 in total

Review 1.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study.

Authors:  J Popović; M Mikov; V Jakovljević
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Apr-Jun       Impact factor: 2.441

Review 3.  Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.

Authors:  G Palareti; C Legnani
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

4.  Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.

Authors:  H J G Desirée van den Bongard; Rolf W Sparidans; David J P Critchley; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

5.  The role of the intestinal microflora in the reductive metabolism of acenocoumarol in man.

Authors:  H H Thijssen; L G Baars; M J Hazen; A E Van den Bogaard
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

Review 6.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

7.  Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol.

Authors:  H H Thijssen; G M Janssen; L G Baars
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Acenocoumarol's pharmacokinetic: linear or not?

Authors:  Parveen Kumar; Puneet Kapoor; Chhikara Meenu
Journal:  EXCLI J       Date:  2019-08-27       Impact factor: 4.068

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.